ReviewFrontiers in cardiovascular medicine2023
Research progress of quercetin in cardiovascular disease.
Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Quercetin-associated cardioprotection in preclinical myocardial ischemia-reperfusion injury: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Quercetin in the Prevention of Induced Periodontal Disease in Animal Models: A Systematic Review and Meta-Analysis.Nutrients · 2024Pooled it
- Quercetin as a Multifunctional Flavonol: Molecular Insights and Therapeutic Applications.Molecules (Basel, Switzerland) · 2026Review
- Role of Plant-Derived Antioxidants in Oxidative Stress-Associated Myocardial Infarction: Structure-Activity Relationship (SAR)-Based Mechanistic Insights.Molecules (Basel, Switzerland) · 2026Review
- Cardiovascular Nanomedicine: Breakthroughs in Therapy-Challenges in Safety and Cardiotoxic Risks: A Comprehensive Review of Inorganic Nanoparticles.Cardiovascular toxicology · 2026Review
- Combined Probiotics and Phenolics in Western Diet-fed Rats Enhance Parasympathetic Tone in the Gut-Brain Axis by Attenuating Inflammasome Signaling, and Reshaping Gut Microbiome.Probiotics and antimicrobial proteins · 2026Article
- Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Matrix-Driven Modulation of Phenolic Profiles fromMolecules (Basel, Switzerland) · 2026Article
- STAT-Mediated Mitochondrial Regulation in Cardiovascular Diseases: Mechanistic Insights and STAT3-Focused Therapeutic Strategies.Biomolecules · 2026Review
- Oxidative Stress and Its Role in Vascular Damage and Atherosclerosis.International journal of molecular sciences · 2026Review
- Quercetin Ameliorates Skeletal Muscle Fibrosis After Injury by Interfering with Macrophage-Myofibroblast Transition.Journal of inflammation research · 2026Article
- Effects of the Brazilian Native Fruit Jaboticaba (Foods (Basel, Switzerland) · 2025Article
- Polyphenol-RichPharmaceutics · 2025Article
- Histone deacetylase 4: A therapeutic target for cardiovascular diseases (Review).International journal of molecular medicine · 2025Review
- Pharmacological Overview of Bioactive Natural Products fromPlants (Basel, Switzerland) · 2025Review
- Review
- An Up-to-Date Review of Traditional Chinese Medicine in the Treatment of Atherosclerosis: Components, Mechanisms, and Therapeutic Potentials.Phytotherapy research : PTR · 2025Review
- Potential of Quercetin as a Promising Therapeutic Agent Against Type 2 Diabetes.Molecules (Basel, Switzerland) · 2025Review
- High-Tyrosol/Hydroxytyrosol Extra Virgin Olive Oil Enhances Antioxidant Activity in Elderly Post-Myocardial Infarction Patients.Antioxidants (Basel, Switzerland) · 2025Article
- Deciphering the angiogenic potential of Zhishi Xiebai Guizhi decoction in coronary heart disease: an in-depth network pharmacology and experimental investigation.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin is one of the most common flavonoids. More and more studies have found that quercetin has great potential utilization value in cardiovascular diseases (CVD), such as antioxidant, antiplatelet aggregation, antibacterial, cholesterol lowering, endothelial cell protection, etc. However, the medicinal value of quercetin is mostly limited to animal models and preclinical studies. Due to the complexity of the human body and functional structure compared to animals, more research is needed to explore whether quercetin has the same mechanism of action and pharmacological value as animal experiments. In order to systematically understand the clinical application value of quercetin, this article reviews the research progress of quercetin in CVD, including preclinical and clinical studies. We will focus on the relationship between quercetin and common CVD, such as atherosclerosis, myocardial infarction, ischemia reperfusion injury, heart failure, hypertension and arrhythmia, etc. By elaborating on the pathophysiological mechanism and clinical application research progress of quercetin's protective effect on CVD, data support is provided for the transformation of quercetin from laboratory to clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.